The PCCTC at ASCO 2025

Written By Kristofer Prepelica, PhD

The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce that science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at this year’s annual meeting of the American Society of Clinical Oncology (ASCO). Through the collaborative nature and intellectual synergy of our leadership, the PCCTC remains poised to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel therapies and validated biomarkers.


Kristofer Prepelica, PhD
Next

Dr. Howard I. Scher Honored with Richard D. Williams, MD Prostate Cancer Research Excellence Award